AstraZeneca says COVID-19 vaccine now 76% effective after updating U.S. trial data

Click to play video: 'Negative headlines no help to AstraZeneca COVID-19 vaccine'
Negative headlines no help to AstraZeneca COVID-19 vaccine
WATCH: Negative headlines no help to AstraZeneca COVID-19 vaccine – Mar 23, 2021

AstraZeneca said its COVID-19 vaccine was 76% effective at preventing symptomatic illness in a new analysis of its major U.S. trial — a tad lower than the level announced earlier this week in a report that was criticized for using outdated information.

U.S. health officials had publicly rebuked the drugmaker for not using the most up-to-date information when it published an interim analysis on Monday that said the vaccine was 79% effective.

The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile and Peru. The earlier interim data was based on 141 infections through Feb. 17.

“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca said in a statement.

Story continues below advertisement

AstraZeneca said it plans to seek U.S. emergency use authorisation in the coming weeks and the latest data has been presented to the independent trial oversight committee, the Data Safety Monitoring Board.

Click to play video: 'Outdated data from AstraZeneca’s U.S. vaccine trial doesn’t change recommendations: Health Canada'
Outdated data from AstraZeneca’s U.S. vaccine trial doesn’t change recommendations: Health Canada

AstraZeneca reiterated on Thursday that the shot, developed with Oxford University, was 100% effective against severe or critical forms of the disease. It also said the vaccine showed 85% efficacy in adults 65 years and older.

The latest health and medical news emailed to you every Sunday.

“A lot of us were waiting for this large, well-constructed and reported Phase III study,” said Paul Griffin, a professor at the University of Queensland.

“This appears to be a very effective vaccine with no safety concerns. Hopefully, this should now give people the confidence that this vaccine is the right one to continue to use moving forward,” he said, adding that he and his parents have taken the vaccine.

Story continues below advertisement

The updated 76% efficacy rate compares with rates of about 95% for vaccines from Pfizer/BioNTech and Moderna.

The AstraZeneca vaccine is, however, seen as crucial in tackling the spread of COVID-19 across the globe, not just due to limited vaccine supply but also because it is easier and cheaper to transport than rival shots. It has been granted conditional marketing or emergency use authorisation in more than 70 countries.

The highly unusual rebuke from U.S. health authorities had marked a fresh setback for the vaccine that was once hailed as a milestone in the fight against the COVID-19 pandemic, but has been dogged by questions over its effectiveness and possible side-effects.

The shot has faced questions since late last year when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing error.

Then this month, more than a dozen countries temporarily suspended giving out the vaccine after reports linked it to a rare blood clotting disorder in a very small number of people.

Click to play video: 'U.S. trials of AstraZeneca COVID-19 vaccine prove its efficacy and safety, Dr. Fauci says'
U.S. trials of AstraZeneca COVID-19 vaccine prove its efficacy and safety, Dr. Fauci says

The European Union’s drug regulator said last week the vaccine was clearly safe, but Europeans remain skeptical about its safety.

Story continues below advertisement

Health Canada has also reaffirmed the vaccine’s safety, but on Wednesday updated the label on AstraZeneca vials to include information about the blood clot reports.

It also distributed guidance for health-care professionals on potential symptoms to monitor.

(Reporting by Rocky Swift in Tokyo, Peter Henderson in San Francisco and Shubham Kalia in Bengaluru; Writing by Miyoung Kim; Editing by Edwina Gibbs)

Sponsored content